Gilead Sciences Valuation Overview

GILD -- USA Stock  

USD 73.27  0.93  1.29%

Gilead Sciences retains regular Real Value of $83.6525 per share. The prevalent price of the corporation is $73.27. At this time the corporation appears to be under valued. Macroaxis calculates value of Gilead Sciences from evaluating the corporation fundamentals such as Current Valuation of 100.05B, Return On Asset of 10.77% and Return On Equity of 9.97% as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we encourage to acquire undervalued assets and to sell overvalued assets since at some point stocks prices and their ongoing real values will come together.

Gilead Science took a bad hit when their bet on a medical trial failed.  Subsequently, their stock price has come down considerably. But, the company is still profitable and is very focused on growth ahead.  Also, market forces should easily push the stock price higher than where it is when looked at from a price-to-earnings ratio.  For that matter, by any matrix, the stock is cheap and should go higher.  

Valuation Drivers Correlation
Click cells to compare fundamentals   View All Correlations
Gilead Sciences Valuation Data Drivers
Net Income Per Employee    Enterprise Value    Market Capitalization    
Gilead Sciences Market Cap
Gilead Sciences is one of the top stocks in market capitalization category among related companies. Market capitalization of Biotechnology industry is currently estimated at about 103.16 Billion. Gilead Sciences totals roughly 96.15 Billion in market capitalization claiming about 93% of stocks in Biotechnology industry.
Capitalization  Valuation  Workforce  Total debt  Revenue
Horizon     30 Days    Login   to change
Gilead Sciences is rated # 4 in beta category among related companies. It is rated below average in price to sales category among related companies fabricating about  2.96  of Price to Sales per Beta.

Current Market Valuation

Gilead Sciences Valuation Boundaries

Under Valued
October 23, 2018
Market Value
Real Value
Target Odds
Gilead Sciences is not too risky asset. Calculation of real value of Gilead Sciences is based on 1 month time horizon. Increasing Gilead Sciences time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.

Valuation Basics

Gilead Sciences Enterprise Value Fundamentals

Quick Ratio2.81
Earnings Quarterly Growth-40.90%
Revenue Growth-20.90%
Payout Ratio129.76%
Enterprise Value To Ebitda8.18
Earnings Growth-40.30%
Enterprise Value To Revenue4.31

Valuation Indicators

Gilead Sciences Valuation Fundamental Ratios

Please also check Risk vs Return Analysis. Please also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.